Shanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol

MT Newswires Live

2024/10/07

Shanghai Pharmaceuticals Holding's (HKG:2607, SHA:601607) subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.

The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.

Price (HKD): $14.58, Change: $+0.48, Percent Change: +3.40%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2473142992"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473142992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473142992?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473142992","market":"hk","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals Holding's (HKG:2607, SHA:601607) subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.</p><p>The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.</p><p>Price (HKD): $14.58, Change: $+0.48, Percent Change: +3.40%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-07 13:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Shanghai Pharmaceuticals Holding's (HKG:2607, SHA:601607) subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.</p><p>The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.</p><p>Price (HKD): $14.58, Change: $+0.48, Percent Change: +3.40%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健護理產品經銷商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473142992","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473142992","pubTimestamp":1728280672,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals Holding's  subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.Price : $14.58, Change: $+0.48, Percent Change: +3.40%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK1197":"保健护理产品经销商","BK0175":"白马股","BK4585":"ETF&股票定投概念","BK4526":"热门中概股","BK4023":"应用软件","BK0196":"行业龙头","BK4588":"碎股","BK0187":"一线龙头","BK0209":"零售","02607":"上海医药","BK0028":"国家队","BK0099":"上海本地重组","BK0188":"融资融券","BK0184":"上海国资改革","BK0012":"证金概念","BK0097":"医药电商","BK0183":"MSCI概念","BK0020":"浦东新区"},"translate_title":"上海医药子公司获准上市阿法骨化醇","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"02607":0.9},"content_text":"Shanghai Pharmaceuticals Holding's (HKG:2607, SHA:601607) subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.Price (HKD): $14.58, Change: $+0.48, Percent Change: +3.40%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}